Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines

The epidermal growth factor receptor (EGFR, HER1) is a therapeutic target in head and neck squamous cell carcinoma (HNSCC). After initial promising results with EGFR‐targeted therapies such as cetuximab, therapeutic resistance has become a major clinical problem, and new treatment options are theref...

Descripción completa

Detalles Bibliográficos
Autores principales: De Pauw, Ines, Lardon, Filip, Van den Bossche, Jolien, Baysal, Hasan, Fransen, Erik, Deschoolmeester, Vanessa, Pauwels, Patrick, Peeters, Marc, Vermorken, Jan Baptist, Wouters, An
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983215/
https://www.ncbi.nlm.nih.gov/pubmed/29603584
http://dx.doi.org/10.1002/1878-0261.12197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983215/
https://www.ncbi.nlm.nih.gov/pubmed/29603584
http://dx.doi.org/10.1002/1878-0261.12197

Ejemplares similares